Efficacy News and Research

RSS

BioCis Pharma starts phase IIa clinical testing of ProtoCure in atopic dermatitis

BioCis Pharma Ltd a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology.

7 Nov 2008

GSK initiates major seasonal influenza vaccine efficacy trial

GlaxoSmithKline (GSK) announced today that it has started a worldwide clinical efficacy trial to evaluate an innovative vaccine for the prevention of seasonal influenza.

6 Nov 2008

SALVAT submits complete response to FDA approvable letter for CETRAXAL

SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers).

6 Nov 2008

BioLife Solutions submits FDA master file on HypoThermosol preservation and storage media for cells, tissues

BioLife Solutions Inc. has announced that it has submitted a Master File to the United States Food and Drug Administration (FDA) for the Company's HypoThermosol preservation media product.

6 Nov 2008

Wide variability in rheumatoid arthritis drug Methotrexate suggests alternative dosing should be considered

Methotrexate (MTX) is commonly used to treat rheumatoid arthritis (RA) and is suggested as the "anchor" drug in treating the disease.

5 Nov 2008

Safety and efficacy of febuxostat for gout examined

The goal in treating patients with gout is to reduce acute attacks by lowering serum urate levels, which are usually high in this disease.

5 Nov 2008

New drug tricks the body into burning off fat

French scientists have found a drug they say tricks the body into burning off fat - and it even works on a high-fat diet.

5 Nov 2008

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

4 Nov 2008

New findings on STEP HIV vaccine trial

The study is the result of the collaboration between scientists at the Institut de Genetique Moleculaire de Montpellier, Universite Montpellier I & II, Montpellier, France, the Centre Hospitalier Universitaire Vaudois (CHUV) and at the Swiss Vaccine Research Institute, University of Lausanne, Lausanne, Switzerland.

4 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

Pfizer's Toviaz (fesoterodine fumarate) receives FDA approval for the treatment of overactive bladder

Pfizer Inc has announced that the U.S. Food and Drug Administration (FDA) approved Toviaz (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms.

2 Nov 2008

Cimzia study shows reduction of symptoms and progression of rheumatoid arthritis

UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.

31 Oct 2008

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.

31 Oct 2008

GSK to acquire Genelabs Technologies

GlaxoSmithKline and Genelabs Technologies, Inc announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).

29 Oct 2008

FDA grants tentative approval for 75th generic anti-retroviral drug

The Food and Drug Administration within the U.S. Department of Health and Human Services (HHS) has reached the milestone of the 75th anti-retroviral generic drug approved or tentatively approved as part of President Bush's Emergency Plan for AIDS Relief (PEPFAR).

29 Oct 2008

How drug companies covertly promote off-label drug use

Off-label prescription of a drug is generally legal, but promotion of off-label uses by a drug manufacturer is illegal. In an article in this week's PLoS Medicine, two physician researchers describe the techniques that drug companies use to covertly promote off-label use, even when such promotion is illegal.

28 Oct 2008

Scientists discover a catalytic antibody that degrades a known appetite stimulant

The antibody works against the gastric hormone ghrelin (pronounced "grell-in"), which has been linked to weight gain and fat storage through its metabolic actions. These findings point towards a potentially novel treatment for obesity that would interfere directly with the some of the biological mechanisms determining weight.

28 Oct 2008

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Galapagos NV has announced that Nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication.

27 Oct 2008

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.

27 Oct 2008

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

26 Oct 2008

Efficacy News and Research

BioCis Pharma starts phase IIa clinical testing of ProtoCure in atopic dermatitis

GSK initiates major seasonal influenza vaccine efficacy trial

SALVAT submits complete response to FDA approvable letter for CETRAXAL

BioLife Solutions submits FDA master file on HypoThermosol preservation and storage media for cells, tissues

Wide variability in rheumatoid arthritis drug Methotrexate suggests alternative dosing should be considered

Safety and efficacy of febuxostat for gout examined

New drug tricks the body into burning off fat

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

New findings on STEP HIV vaccine trial

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

Pfizer's Toviaz (fesoterodine fumarate) receives FDA approval for the treatment of overactive bladder

Cimzia study shows reduction of symptoms and progression of rheumatoid arthritis

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)

GSK to acquire Genelabs Technologies

FDA grants tentative approval for 75th generic anti-retroviral drug

How drug companies covertly promote off-label drug use

Scientists discover a catalytic antibody that degrades a known appetite stimulant

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News